COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
Public ClinicalTrials.gov record NCT06763549. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications from the COR ECG Wearable
Study identification
- NCT ID
- NCT06763549
- Recruitment status
- Enrolling by invitation
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Peerbridge Health, Inc
- Industry
- Enrollment
- 15,000 participants
Conditions and interventions
Conditions
- Apnea, Obstructive
- Atrial Enlargement
- Atrial Fibrillation (AF)
- CRT And/or ICD
- Cardiac Output Measurement
- Cardiac Output, Low
- Cardiomyopathies, Primary
- Cardiopulmonary Failure
- Conduction Abnormalities
- Conduction Defect
- HFpEF - Heart Failure with Preserved Ejection Fraction
- HFrEF - Heart Failure with Reduced Ejection Fraction
- Heart Block
- Heart Decompensation
- Heart Failure
- Hypercalcemia
- Hyperkalemia
- Hypertrophy
- Hypocalcemia
- Infarction
- Ischemic Cardiovascular Disease
- LV Dysfunction
- LVF
- Myocardial Infarction (MI)
- Pacing
- Pacing Induced Dyssynchrony
- Pericarditis
- QT Prolongation
- RSA
- Respiratory Impedance
- STEMI
- STEMI (ST Elevation MI)
- Silent Ischemia
- Sleep Related Breathing Disorder
- Stroke Volume
- Stroke Volume Variation
- Sudden Cardiac Death Due to Cardiac Arrhythmia
- Syncopation
- Syncope
- Valvular Diseases
- Ventricular Arrhythmia
Interventions
- SUBPROTOCOL A Device
- SUBPROTOCOL B Device
- SUBPROTOCOL C Device
- SUBPROTOCOL D Device
- SUBPROTOCOL E Device
- SUBPROTOCOL F Device
- SUBPROTOCOL G Device
- SUBPROTOCOL H Device
Device
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2024
- Primary completion
- Apr 14, 2026
- Completion
- Apr 14, 2026
- Last update posted
- Jan 7, 2025
2024 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Peerbridge Health, Melbourne, Florida 32935 | Melbourne | Florida | 32935 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06763549, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 7, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06763549 live on ClinicalTrials.gov.